
Regarding biotech M&A, Credit Suisse Group AG (NYSE:CS) doesn't think there will be more megamergers in the next 12 to 18 months --
we could have told you that.
CS did list, however, what it sees as smaller prime acquisition targets alongside possible suitors:
- Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) by Abbott Laboratories (NYSE:ABT), Bristol-Myers Squibb Co. (NYSE:BMY) or Eli Lilly and Co. (NYSE:LLY);
- Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) by Eli Lilly;
- Biomarin Pharmaceutical Inc.(NASDAQ:BMRN) by Abbott, Bristol-Myers Squibb or Eli Lilly;
- Rigel Pharmaceutical Inc. (NASDAQ:RIGL) by Abbott, Bristol Myers Squibb or Johnson & Johnson (NYSE:JNJ);
- Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) by Forest Laboratories Inc. (NYSE:FRX); and
- Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) by Bristol-Myers Squibb, Gilead Sciences Inc. (NASDAQ:GILD) or Johnson & Johnson.
Credit Suisse "sees Alexion and Vertex as
targets with the most merit, both of which are viewed bullishly on fundamentals and potential deals providing further upside."
A Citigroup Investment Research analyst recently
upgraded Alexion to a "buy" from "hold," citing additional sales opportunities from a drug that treats a rare chronic disease called paroxysmal nocturnal hemoglobinuria, which causes a breakdown of red blood cells and leads to anemia.
See what's going on at Vertex in this
istockanalyst report. -
Baz Hiralal
Join Corporate Dealmaker's LinkedIn forum